-

Best’s Commentary: COVID-19 Impact on U.S. Health Insurance Companies Smaller Than Expected

OLDWICK, N.J.--(BUSINESS WIRE)--The first-quarter 2020 earnings of publicly traded U.S. health insurance companies show that the impact of the COVID-19 pandemic has been less severe than anticipated, according to a new AM Best commentary.

The Best’s Commentary, titled, “COVID-19 Impact on Health Insurance Companies Smaller Than Expected,” notes that while there have been more than an estimated 1.5 million reported cases of COVID-19 across the United States, the majority of the individuals diagnosed have not been hospitalized and have been isolating at home. For health insurance companies, the decline in medical care for non-COVID conditions has more than offset the impact from COVID-19 claims. Since the deferral of medical care did not begin until the last few weeks of March, concurrent with the dramatic rise of COVID-19 cases, the impact was not meaningful in first-quarter statutory earnings. AM Best expects claims to increase in the second half of 2020, as many states re-open and allow providers to schedule elective procedures and conduct routine care office visits, assuming the pandemic subsides.

According to the commentary, first-quarter 2020 statutory earnings will decline year over year, primarily driven by the return of the health insurer fee (HIF), which is expensed in full in the first quarter. Health insurers largely pass on the HIF, which is approximately $15.5 billion in 2020, via premiums, and as a result, earnings will normalize over the course of the year.

Claims volumes could decline again if there were to be a second wave of COVID-19, which could again lead to the deferral of non-essential surgeries and visits. Additionally, consumers and providers have embraced tele-health/virtual visits as an alternative to in office care, a trend that is likely to continue. Certain carriers have reported that the number of tele-health visits increased substantially in the first quarter of 2020, and are even paying at parity in the short-term with an actual face-to-face office visit.

The impact from job losses also has not yet manifested into enrollment decline for health insurance companies; however, the risk of enrollment losses increases the longer the COVID-related closures persist. AM Best is maintaining a stable market segment outlook on the U.S. health insurance segment, and will continue to monitor enrollment, premium and new business trends as they develop in the second quarter.

To access the full copy of this commentary, please visit http://www3.ambest.com/bestweek/purchase.asp?record_code=297562.

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in New York, London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2020 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

Joseph Zazzera
Director
+1 908 439 2200, ext. 5797
joseph.zazzera@ambest.com

Christopher Sharkey
Manager, Public Relations
+1 908 439 2200, ext. 5159
christopher.sharkey@ambest.com

Sally Rosen
Senior Director
+1 908 439 2200, ext. 5280
sally.rosen@ambest.com

Jim Peavy
Director, Public Relations
+1 908 439 2200, ext. 5644
james.peavy@ambest.com

AM Best


Release Versions

Contacts

Joseph Zazzera
Director
+1 908 439 2200, ext. 5797
joseph.zazzera@ambest.com

Christopher Sharkey
Manager, Public Relations
+1 908 439 2200, ext. 5159
christopher.sharkey@ambest.com

Sally Rosen
Senior Director
+1 908 439 2200, ext. 5280
sally.rosen@ambest.com

Jim Peavy
Director, Public Relations
+1 908 439 2200, ext. 5644
james.peavy@ambest.com

More News From AM Best

Best’s Commentary: Health Insurers Evaluating Balance Between Pharmacy Costs and Long-Term Value of GLP-1 Therapies

OLDWICK, N.J.--(BUSINESS WIRE)--As pharmacy cost trends continue to rise and clinical evidence evolves, health insurers face a fundamental question on whether improvements in long-term morbidity and the potential for improved mortality outcomes ultimately justify significant investments in GLP-1 therapies, according to a new AM Best commentary. The Best’s Commentary, “GLP-1 Therapies: Evaluating the Balance Between Pharmacy Costs and Long-Term Value,” states that GLP-1 therapies have become one...

AM Best Downgrades Credit Ratings of A-CAP Group Members; Maintains Under Review With Negative Implications Status

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has downgraded the Financial Strength Rating (FSR) to C+ (Marginal) from B (Fair) and the Long-Term Issuer Credit Rating (Long-Term ICR) to “b-” (Marginal) from “bb+” (Fair) of Atlantic Coast Life Insurance Company (Charleston, SC) and Sentinel Security Life Insurance Company (Salt Lake City, UT). Both companies are collectively referred to as A-CAP Group. Concurrently, AM Best has maintained the under review with negative implications status for these Cre...

AM Best to Deliver Presentation at 2026 ACLI Annual Conference

OLDWICK, N.J.--(BUSINESS WIRE)--AM Best will speak at the American Council of Life Insurers (ACLI) Annual Conference, which will take place Oct. 14-16, 2026, in Orlando, FL. Kenneth Frino, managing director, and Erik Miller, senior director, both of AM Best, will deliver a presentation, titled, “Life and Annuity Segment in Transition,” during which they will focus on operating results across the life/annuity segment, as well as investment strategies, rating activity trends and AM Best’s segment...
Back to Newsroom